EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Phenoconversion of CYP3A4 , CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study

Rachel Conyers iD, Tayla Stenta iD, Andrew A Somogyi iD, Carl Kirkpatrick iD, Andreas Halman iD, Sophie Wang iD, Claire Moore iD, Dhrita Khatri iD, Elizabeth Williams iD, Roxanne Dyas iD, Tim Spelman iD, David A Elliott iD und 2 weitere

Clinical and Translational Science · 2025-04 · 18 (4)

DOI: 10.1111/cts.70209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 21.04.2025. Verfasst von Rachel Conyers und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Australia. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP2D6, Cytochrome P-450 CYP3A, Lymphoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phenoconversion is the discrepancy between genotype‐predicted phenotype and clinical phenotype, due to nongenetic factors. In oncology patients, the impact of phenoconversion on drug selection, efficacy, toxicity, and treatment outcomes is unknown. This study will assess acceptability and feasibility of investigating phenoconversion using probe medications in a pediatric and adolescent and young adult (AYA) oncology population. This prospective, single‐arm, single‐blind, nonrandomized feasibility study, will enroll individuals aged 6–25 years with a new diagnosis of Hodgkin Lymphoma or Non‐Hodgkin Lymphoma. Genotyping will be performed at baseline using whole genome sequencing or targeted panel testing. Longitudinal phenotyping will be conducted throughout the cancer treatment using exogenous oral enzyme‐specific probes, specifically subtherapeutic dextromethorphan (CYP2D6) and omeprazole (CYP2C19, CYP3A4) for enzyme activity assessment. The primary outcome measure will be the proportion of patients who consent to the study and successfully complete baseline and at least two longitudinal time points with valid probe drug metabolic ratio measurements. Secondary outcomes include classification of clinical phenotypes based on probe drug metabolic ratios, probe drug safety, barriers to consent, acceptability of pharmacogenomic and phenoconversion testing, longitudinal genotype/phenotype concordance, inflammatory profiles, and patient and disease factors influencing phenoconversion. The trial has received ethics approval (2023/ETH1954) and is registered at ClinicalTrials.gov (NCT06383338). Findings will be disseminated through peer‐reviewed publications and professional conferences, providing critical insights to advance the understanding of phenoconversion in oncology from pediatrics to adults. These results will help shape future research and drive the implementation of more personalized precision medicine strategies for all people with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3ALymphomaHodgkin DiseaseHumansAdolescentChildYoung AdultProspective StudiesDextromethorphanAdultSingle-Blind MethodMaleFeasibility StudiesFemalePhenotypeOmeprazoleGenotype

Stichwörter der Autor:innen

AustraliaPhenoconversiononcologypharmacogenomic implementationpharmacogenomics

Substanzen

Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6CYP2C19 protein, humanDextromethorphanCytochrome P-450 CYP3ACYP3A4 protein, humanOmeprazole

Autor:innen und Institutionen

  • Cancer Therapies Group, Murdoch Children's Research Institute, Parkville, Australia.
  • Department of Paediatrics, The University of Melbourne, Parkville, Australia.
  • Children's Cancer Centre, The Royal Children's Hospital, Parkville, Australia.
  • School of Biomedicine, University of Adelaide, Adelaide, Australia.
  • Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia.
  • Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

ORCID-Profile: Rachel Conyers, Tayla Stenta, Andrew A Somogyi, Carl Kirkpatrick, Andreas Halman, Sophie Wang, Claire Moore, Dhrita Khatri, Elizabeth Williams, Roxanne Dyas, Tim Spelman, David A Elliott, Amanda Gwee, Marliese Alexander

Zitieren

APA

Conyers, R., Stenta, T., Somogyi, A. A., Kirkpatrick, C., Halman, A., Wang, S., Moore, C., Khatri, D., Williams, E., Dyas, R., Spelman, T., Elliott, D. A., Gwee, A., & Alexander, M. (2025). Phenoconversion of CYP3A4 , CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study. Clinical and Translational Science, 18(4). https://doi.org/10.1111/cts.70209

Vancouver

Conyers R, Stenta T, Somogyi AA, Kirkpatrick C, Halman A, Wang S, et al. Phenoconversion of CYP3A4 , CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study. Clinical and Translational Science. 2025;18(4). doi:10.1111/cts.70209

BibTeX
@article{Conyers2025,
  author = {Conyers, Rachel and Stenta, Tayla and Somogyi, Andrew A and Kirkpatrick, Carl and Halman, Andreas and Wang, Sophie and Moore, Claire and Khatri, Dhrita and Williams, Elizabeth and Dyas, Roxanne and Spelman, Tim and Elliott, David A and Gwee, Amanda and Alexander, Marliese},
  title = {Phenoconversion of CYP3A4 , CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {4},
  doi = {10.1111/cts.70209}
}
Kostenlos starten →